estimating pharmaceutical expenditure at net prices: … · total pharmaceutical expenditure is...
TRANSCRIPT
ESTIMATING PHARMACEUTICAL EXPENDITURE AT
NET PRICES: IS THE PERCEIVED PROBLEM AS
LARGE AS EXPECTED?
DR JORGE MESTRE-FERRANDIZ
A LITTLE ABOUT ME…
• Economist by training
• Currently working as a freelance
• Used to work for the Office of Health Economics, London
• Areas of interest: pharmaceutical policy
• Research/academia and consulting experience
2
AGENDA
1. Introduction & Context
2. Objective of study
3. Methods
4. Results
5. Conclusions
3
1. INTRODUCTION & CONTEXT
• There is an assumption that biopharmaceutical expenditure is unsustainable and driven by high prices
4
What will
pharmaceutical
expenditure look
like in the future in
Europe?
What level
of pharma
expenditure can be
considered sustainable
(and optimal)?
But there are
still questions
to be
answered…
1. INTRO & CONTEXT: HEALTHCARE EXPENDITURE IS EXPECTED TO GROW AT AROUND 3%
BY 2030 (2.1% FOR HIGH INCOME COUNTRIES)
• Health spending is associated with economic development but remains variable across world regions
Source: Global Burden of Disease Health Financing Collaborator Network. Future and potential spending on health 2015–40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries. The Lancet 2017;389(10083):2005–30
5
1. INTRO & CONTEXT: OECD DATA SUGGEST THE PROPORTION OF HEALTHCARE
EXPENDITURE SPENT ON MEDICINES IS FALLING
• Growth in overall healthcare expenditure is a challenge for publicly funded healthcare systems; however,
this trend might not not fuelled by disproportionate increases in the cost of medicines
Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/196
1. INTRO & CONTEXT: …BUT DIFFERENT PICTURE FOR GREECE?
7Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/19
1. INTRO & CONTEXT: IMPORTANCE OF OFF-PATENT SEGMENT TO GENERATE SAVINGS
• Within the EU, the availability of generic medicines and patent expiries has helped offset spending on
branded medicines
Note: Europe includes Germany, France, Italy, UK, Spain, Poland, Belgium, Switzerland, Austria, Netherland, Greece, Finland, Hungary, Portugal, Ireland, Czech Republic, Norway and Slovakia
1. IMS Health: The Role of Generic Medicines in Sustaining Healthcare Systems: A European Perspective. June 2015; accessed June 2018
8
1. INTRO & CONTEXT: BUT UPTAKE OF GENERICS UNEVEN…MANY REASONS
Source: OECD: https://stats.oecd.org/Index.aspx?DataSetCode=HEALTH_PHMC 9
1. INTRO & CONTEXT: FORECASTS ARE USED TO ESTIMATE THE GROWTH AND IMPACT OF MEDICINE EXPENDITURE BUT ARE TYPICALLY BASED ON LIST PRICES
This forecast is based on real sales data but does not adjust for confidential discounts and rebates
1. IQVIA forecast
10
1. INTRO & CONTEXT: IN THE LAST DECADE, THERE HAS BEEN AN INCREASED USE OF NET
PRICE DISCOUNTS, REBATES AND MANAGED ENTRY AGREEMENTS ACROSS EUROPE
Managed entry agreements and rebates are mechanisms increasingly used for reimbursing high cost medicines
1. VFA. The German pharmaceutical market. 2018. Available from: www.vfa.de/en/statistics/statistics-2012-am-deutschland1; accessed May 2018
2. Tettamanti A. Managed entry agreement in the Italian market between June 2005 and June 2015. ISPOR PHP220 poster
3. Pharmaphorum. Patient access schemes: a look behind the scenes. 2015. Available from: www.pharmaphorum.com/views-and-analysis/patient-access-
schemes-a-look-behind-the-scenes/; accessed May 2018
11
1. INTRO & CONTEXT: AND USE OF ERP EXPANDING…
12
Source: WHO, 2018
Source: Panteli et al., 2017 Source: WHO/WTO report of the workshop on differential pricing and financing of essential drugs, available at www.wto.org.
AGENDA
1. Introduction & Context
2. Objective of study
3. Methods
4. Results
5. Conclusions
13
2. OBJECTIVE OF STUDY
• Estimate future pharmaceutical expenditure growth rates in France, Germany, Italy, Spain and the UK (EU5) at
net prices by adjusting the established IQVIA analysis (‘list forecast’) for discounts that are not currently
incorporated (‘net forecast’).
14
AGENDA
1. Introduction & Context
2. Objective of study
3. Methods
4. Results
5. Conclusions
15
3. METHODS: A FOUR-STEP APPROACH WAS USED TO ADJUST THE IQVIA FORECAST
METHODOLOGICAL APPROACH OF THE ADJUSTED FORECAST1
Rx= expenditure on medicines that require a prescription
Historical list estimate (2010–2016)
Identify IQVIA historical list
estimates of pharmaceutical
expenditure (2010–2016).
Expenditure on branded medicines
and generics are not reported
separately.
1
1. Espin J et al (2018). Projecting Pharmaceutical Expenditure in EU5 to 2021. Applied Health Economics and Health Policy Journal
List forecast (2017–2021)
Analyse and plot historical volume
and list price data; develop baseline
projections using exponential
smoothing techniques; assess and
quantify events, and apply to baseline
projections.
2
Historical net estimate (2010–2016)
Estimate historical discounts
observed in each country (not
included in historical list estimates)
to create historical net estimates
(2010–2016).
3Net forecast (2017–2021)
Adjust list forecast for each
country to reflect historical net
estimates; estimation of net forecast.
4
16
3. METHODS – MOVING FROM LIST TO NET HISTORIC EXPENDITURE
17
3. METHODS – SPAIN: OVERVIEW OF DISCOUNTS AND REBATES FOR MANUFACTURERS
100
-2%
98
-7.5%*
92.5
-~20%
72.5%
List price Compulsory
paybacks
National level
- 27.5%
Price after
payback
Product
discounts
via
invoicing
Retail setting drugs
Industry rebates – Not
applicable to date
Hospital drugs
Reimburse
ment
price
(net price)
* For orphan dugs
it is 4%
Ambulatory
off-patent
products
Hospital level
Additional hospital
discounts over and
above the national
discounts
Tenders/discountsTenders
Regional level
- 40%**
** Only in Andalucia
Negotiated
discounts
18
AGENDA
1. Introduction & Context
2. Objective of study
3. Methods
4. Results
5. Conclusions
19
4. RESULTS: TOTAL PHARMACEUTICAL EXPENDITURE IS FORECAST TO GROW AT A RATE OF 1.5
TO 2% CAGR OVER THE NEXT 5 YEARS
The forecast figure could be as low as 0.5 to 1% if there is greater biosimilar use than current conservative
estimates
1. Espin J et al (2018). Projecting Pharmaceutical Expenditure in EU5 to 2021. Applied Health Economics and Health Policy Journal 20
4. RESULTS: EU5
21
AGENDA
1. Introduction & Context
2. Objective of study
3. Methods
4. Results
5. Conclusions
22
5.CONCLUSIONS
• Increasing frequency and magnitude of confidential discounts, including MEAs, rebates and discounts =>
growing divergence between list and net prices for medicines in Europe.
• Many drivers, including increasing financial pressures within health systems, and policies such as external
reference pricing, and a shift in pharmaceutical innovation from retail to hospital settings in many countries
with most new medicines for immunological and cancer conditions.
• We should analyse jointly with outcomes achieved from their use – complex task!!
• After adjusting for discounts and rebates, net expenditure growth in EU5 is predicted to be
approximately 1.5% CAGR over the next five years. This is below predicted healthcare expenditure
growth in Europe and in line with long-term economic growth rates
23
5. CONCLUSIONS
• Latest OECD data seem to confirm the conclusions: drug spending has grown the least among functions of
health spending between 2004 and 2016
24
Thanks for your attention!
Dr Jorge Mestre-Ferrandiz
Independent Economics Consultant
Visiting Fellow, Office of Health Economics
Profesor Asociado, Universidad Carlos III, Madrid
Profesor de Health Economics de FT/Instituto de Empresa (IE) Business School
Director, Oxford Martin Programme on Affordable Medicines, Oxford Martin School, University of Oxford
Honorary Visiting Lecturer, Department of Economics, City University London
Views expressed are my own
Email: [email protected]
25
Back-up slides
HEALTH SPENDING
Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/19
PHARMACEUTICAL SPENDING (1/3)
Pharmaceutical spending covers expenditure on prescription medicines and self-medication, often referred to as over-the-counter products. In some countries, other medical non-durable goods are also included. Pharmaceuticals consumed in hospitals and other health care settings are excluded. Final expenditure on pharmaceuticals includes wholesale and retail margins and value-added tax. Total pharmaceutical spending refers in most countries to “net” spending, i.e. adjusted for possible rebates payable by manufacturers, wholesalers or pharmacies. This indicator is measured as a share of total health spending, in USD per capita (using economy-wide PPPs) and as a share of GDP
Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/19
PHARMACEUTICAL SPENDING (2/3)
Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/19
PHARMACEUTICAL SPENDING (3/3)
Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/19
PHARMACEUTICAL SPENDING: GREECE
Source: OECD. Pharmaceutical spending (indicator). 2018: Available at: https://data.oecd.org/healthres/pharmaceutical-spending.htm; accessed 25/03/19